BCL2 and cancer: Our models showed that miRNAs and TFs are the greatest contributors to the explanation of BCL2 gene expression variation, conferring a predictive gain of 15–60% in 9 of our 21 cancers for miRNA and <25% in 11 of our 21 cancers for TFs (Fig. 3).